Military nurse attends VE Day celebrations
A senior nurse who has served in the military and treated soldiers was invited to VE (Victory in Europe) Day events in London this week.
Robin McMahon, a healthcare worker from the Royal Wolverhampton NHS Trust, has been deployed to countries including Afghanistan and Poland.
In recognition of his military role, he was invited to a service at St Paul's Cathedral and a concert at Horse Guards Parade to mark the 80th anniversary of VE Day on Thursday.
Mr McMahon said it had been "a real privilege" to attend the events, especially as World War Two veterans and Blitz survivors had also been there.
VE Day commemorates the end of fighting in Europe in World War Two on 8 May 1945, after Nazi German forces surrendered to the Allies after nearly six years of conflict.
There were special anniversary events across the country this week, including street parties and flypasts in the West Midlands.
Mr McMahon trained as a nurse in Staffordshire, before taking up paediatric roles in London, Birmingham and Wolverhampton.
His first military role was in the Queen Alexandra's Royal Army Nursing Corps, providing medical care to soldiers in the UK and overseas.
He attended the VE Day events as a member of the Worshipful Company of Nurses, a body that represents the profession.
Mr McMahon currently serves in the 306 Hospital Support Regiment, which is part of the Royal Army Medical Corps based near York. The regiment provides specialist healthcare that is not usually available in field hospitals.
As an Army reservist, he can be recalled in times of need to join operations alongside regular soldiers.
"The beauty of the military is everyone is so motivated and wanting to do their best to help others," he said.
Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
VE Day: What is it, when is it and why do we remember?
WW2's oldest veteran attends VE Day memorial event
Families' VE Day letters show delight and relief
The Royal Wolverhampton NHS Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Residents invited to take part in liver testing
Residents in Stoke-on-Trent are being invited to take part in free liver testing at two local roadshows funded by a doctor who died from cancer. Dr Alison Brind, 63, who specialised in liver disease, worked with patients in Stoke-on-Trent and Staffordshire for more than 25 years. The consultant gastroenterologist, who worked at University Hospitals of North Midlands (UHNM), was diagnosed with pancreatic cancer in 2022 and died in April last year. After identifying people at risk of liver disease at roadshows in 2023, Dr Brind, who raised more than £10,000 for the UHNM charity, decided to fund the scheme for another five years, organisers said previously. Two Love Your Liver roadshows are being held at Stoke City's Bet365 Stadium on Tuesday and at Port Vale Football Club on Wednesday between 10:00 and 16:00 BST. Vanessa Carr, liver clinical nurse specialist, said visitors would be offered a free liver health scan and could also speak to a dedicated liver health team for advice and support. "One in 10 adults in Stoke-on-Trent may have liver disease but be completely unaware because there are usually no symptoms in the early stages," she said. "But the earlier the disease is detected, the better chance there is to reduce and then reverse any damage." Ms Carr said liver disease remained one of the leading causes of premature death in the area. "None of this would have been possible without Dr Alison Brind who has been an absolute inspiration to us over the past 25 years and we continue to work in her memory," she said. Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram. 'Truly inspirational' doctor and fundraiser dies Doctor with cancer 'honoured' by work award 'I want to be remembered for liver disease work' UHNM
Yahoo
2 hours ago
- Yahoo
Hospital parking charges up 108% for consultants
Consultants and some doctors at a hospital have seen staff parking charges increase by more than 100%, a union says. Price rises accompanied the introduction of automatic number plate recognition (ANPR) at James Cook University Hospital in Middlesbrough. A University Hospitals Tees (UHT) spokesperson confirmed £1.8m would be invested in car park improvements over the coming year. The British Medical Association (BMA) has described the new charges as "shocking and unacceptable". Some members of staff on lower salaries would see a decrease in charges but consultants would pay a tariff for a dedicated car park for them, said the UHT. The BMA has said charges for consultants at the hospital have gone up by 108%, with some doctors on specific shift patterns seeing increases in excess of 125%. The price changes will bring the South Tees hospitals in line with the policy of the North Tees and Hartlepool NHS Trust, which has had varied prices for staff over the last 10 years. Dr Andy Thornley, representing the BMA, said: "Charging staff who are just trying to come to work to care for patients at the hospital to make financial gains for a struggling trust is wrong. "Worse still is the unfair charges that patients and their visitors are being forced to pay, with no choice in order to access the hospital. "This is just the latest in what can only be described as chaotic implementation of new parking measures at the hospital, impacting not only consultants but also resident doctors who are still unsure what the new charges will mean for them. "We want assurances that staff who are members of the parking scheme will not be fined additional charges for simply coming to work to care for patients." A UNISON spokesperson reinforced this message, stating that imposing higher parking charges on NHS staff and patients "shows a shocking lack of understanding" of the financial struggle many are facing. The trust has said it is the first increase in two years and that any surplus funds will be diverted into patient care. A spokesperson said: "We understand the price rise is not welcome news, but we have kept the increase as low as possible. "We would like to reassure all our patients and visitors that the income from car parking is used to maintain our car parks including the costs of repairs and maintenance, lighting, gritting and security, all of which helps us to retain our 'Park Mark' Safer Parking Scheme accreditation. "This coming year will see us invest £1.8m in improvements to our car parking." Follow BBC Tees on X, Facebook, Nextdoor and Instagram. Hospital parking charges rise 'necessary' Hospital parking charges to increase Hospital staff protest over planned parking change The James Cook University Hospital
Yahoo
2 hours ago
- Yahoo
ANGLE plc Announces Novel Discoveries Into the Biology of Cancer
PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SURREY / / June 10, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of three new peer-reviewed publications reporting first-in-class research into the biology of cancer and potential therapeutic targets using the Company's Parsortix system. Tumour cell release during surgery for prostate cancer1Professor Klaus Pantel and researchers from the University Medical Center Hamburg-Eppendorf published an article in the Journal of Experimental & Clinical Cancer Research, investigating tumour cell release into the local tumour vein and peripheral veins during surgery in early-stage prostate cancer patients. The study provides first evidence for substantial release of healthy and cancerous cells into the blood during prostatectomy surgery. This research opens a new avenue for the Parsortix system to study the important and under-investigated biology of tumour cell release during surgery to understand the risk they pose to patients, and for the development of strategies to minimise the spread of cancer. Tumour cell release during surgery for ovarian cancer2Professor John O'Leary and researchers from Trinity College Dublin have published similar findings in the European Journal of Surgical Oncology, investigating CTC enrichment from the local tumour vein and peripheral veins during surgery in rare epithelial ovarian carcinomas. They reported higher yields of CTCs and CTC clusters in the local tumour vein when compared to peripheral veins. The study also reported that CTCs were detected in early-stage patients, highlighting the risk of early tumour cell dissemination driving cancer progression even in the initial stages of disease. Overall, the authors state that assessing tumour cell release during surgery is a novel strategy to study the biology of this rare disease. Mechanical conditioning & metastatic implications3Professor Julie Lang and researchers from the Cleveland Clinic have published an article in Cancers, investigating biomechanical adaptions of cells that are associated with increased metastatic potential in breast cancer patients. They studied the expression of 1004 genes via RNA-sequencing that reflect how cancer cells respond to a stiff extracellular matrix described as a mechanical conditioning score. The Parsortix system was utilised to enrich and harvest CTCs from a metastatic cohort of breast cancer patients for analysis and compared these to primary and metastatic tissue. The study analysed RNA from CTCs rather than ctDNA to provide insight into gene expression. They state that: 'When analyzing shed ctDNA, there is no insight into gene expression, but rather only the presence of tumor-specific mutations, which is not directly reflective of dynamic tumor gene expression. In fact, only a very small percentage of DNA mutations are expressed, which is why circulating tumor DNA and RNA from CTCs are not parallel assays'. The study reported that the mechanical conditioning score increases progressively through the metastatic cascade (from the primary tumour to CTCs to the metastatic site) and is associated with increased metastatic potential. These are new insights into the biology of metastatic progression and may guide treatment selection with anti-fibrotic drugs. Overall, these publications further underscore the role of the Parsortix system in helping to advance our understanding of the biology of cancer which will ultimately advance oncology drug discovery and development. Already ANGLE's technology has enabled breakthrough research in a number of areas including the metastatic potential of CTC clusters, new potential biomarkers and a novel drug class. Academic and translational research discoveries made possible by the Parsortix system, have the potential to feed the pipeline of next generation personalised cancer diagnostics and therapeutics, as pharma companies increasingly collaborate with academia4. ANGLE's Chief Scientific Officer, Karen Miller, commented:"We are proud to see ANGLE's technology increasingly being exploited to make novel discoveries into the biology of cancer, which may eventually result in new treatment strategies. With advancing analytical capabilities beginning to realise the vast potential of the circulating tumour cell for its wealth of multiomic information, this contribution to the oncology pipeline will continue to grow. We congratulate these key opinion leaders on their outstanding work, and we look forward to more exciting discoveries in the future." 1. Emurlai, G. et al. Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy. J. Exp. Clin. Cancer Res. 44, 143 (2025). 2. Lewis, F. et al. A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas. Eur. J. Surg. Oncol. 51, (2025). 3. Mouneimne, G. et al. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers 17, 1632 (2025). 4. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
